Genentech Release: ACTEMRA Data Presented at American College of Rheumatology Annual Meeting on Rapid Response and Long-Term Efficacy in People with Rheumatoid Arthritis

Published: Nov 08, 2010

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced updated data from a Phase III study (ROSE) that showed rheumatoid arthritis (RA) patients receiving ACTEMRA® (tocilizumab) experienced a rapid, measured response as early as one week after beginning ACTEMRA, and improvement in disease activity within four weeks. Additionally, combined data from three other Phase III studies showed that RA patients who received ACTEMRA had sustained improvements in signs and symptoms over nearly two years. These data will be presented at the 2010 American College of Rheumatology (ACR) Annual Scientific Meeting in Atlanta, November 7-11, 2010.

Back to news